UPCommons. Portal del coneixement obert de la UPC
Publicación
Artículo científico (JournalArticle)
Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: a systematic review
Background: The design and analysis of randomized clinical trials (RCTs) in filarial diseases such as onchocerciasis, loiasis, and mansonellosis pose unique statistical challenges, including skewed endpoints and limited sample sizes. This systematic review summarizes design and analysis approaches of RCTs conducted in these diseases with a focus on the statistical methodology. Methods and findings: A systematic search was conducted in PubMed and four trial registries to identify RCTs investigating treatments for onchocerciasis, loiasis, and mansonellosis published or registered between 2000 and 2024. We excluded studies focusing on new methods or pharmacokinetics, short reports, and Phase I trials. Forty-four studies met the inclusion/exclusion criteria (23 for onchocerciasis, 16 for loiasis, and 5 for mansonellosis), information was retrieved from the registries, the manuscripts and/or the study protocol. As primary efficacy endpoints, for onchocerciasis studies qualitative endpoints dominated, while quantitative endpoints were more frequently observed for loiasis and mansonellosis. The most frequently reported hypothesis tests for the primary endpoint were the Mann-Whitney U and the chi-squared tests. We found considerable heterogeneity between trials - not only in study-specific parameters such as the number of arms, type of blinding or control group - but also in design parameters or attributes that could be standardized within each disease across studies with similar objectives, such as the primary endpoint, length of follow-up, the analysis method and the primary analysis population. Conclusions: Several trials were well-planned with detailed information provided in either the manuscript or the registry. However, for some trials, information was sparse or incomplete, indicating a need for more structured and transparent reporting. Adopting established frameworks such as CONSORT and ICH E9 (R1) estimand approach would enhance transparency and better align trial objectives, analyses, and reported conclusions., This study is fully supported by the EU project eWHORM (https://www.global-health-edctp3.europa.eu): The eWHORM project (No 101103053, project leader MPH) is supported by the Global Health EDCTP3 Joint Undertaking and its members as well as the Swiss Confederation. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Global Health European and Developing Countries Clinical Trials Partnership (EDCTP3). Neither the European Union nor the granting authority can be held responsible for them. MBR was additionally supported by Grant PID2023-148033OB-C21 funded by MICIU/AEI/10.13039/501100011033 and by FEDER/UE (Spanish Ministry of Science and Innovation, https://www.ciencia.gob.es/en/). MPH is additionally funded by the Deutsche Forschungsgemeinschaft (DFG; https://www.dfg.de/) (HU 2144/3-1 and HU 2144/4-1) and under Germany’s Excellence Strategy—EXC2151-390873048. MPH is a member of the German Center for Infection Research (DZIF; https://www.dzif.de/en) and received funding from the German Center for Infection Research (TTU 09.701). UKS is a group leader funded by the German Center for Infection Research (TTU 09.715). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed